Harmony Biosciences Holdings Inc (HRMY) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Harmony Biosciences Holdings inc   (NASDAQ: HRMY)

Harmony Biosciences Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Harmony Biosciences Holdings Inc in the second quarter 2026?
Harmony Biosciences Holdings inc achieved a return on average equity (ROE) of 20.06 % in its second quarter 2026, which is below Harmony Biosciences Holdings Inc 's average return on equity, which stands at 29.91%.

ROE has advanced compared to 17.19% in the first quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 35 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 739 to 805.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 29.25 % 26.35 % 32.02 % 39.93 % -
Y / Y Net Income Change 89.64 % -28.69 % -54.55 % 10.35 % 243.16 %
Net Income (TTM) in Millions 181 146 159 186 181
Return On Equity (TTM) 20.06 % 17.19 % 19.84 % 24.86 % 26.32 %
HRMY's Total Ranking # 805 # 739 # 580 # 446 # 370
Equity (TTM) in Millions 999 910 870 835 773
Seq. Equity Change 9.76 % 4.61 % 4.2 % 8.03 % 7.29 %
Seq. Net Income Change 132.18 % 44.48 % -55.79 % 27.88 % -12.7 %

Back to HRMY Management Effectiveness >> HRMY's 5 Years Annual ROE >> Compare HRMY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 36
Sector # 85
Overall # 805

Return On Equity Statistics
High Average Low
62.81 %
29.91 %
9.66 %
(Sep 30 2022)  





HRMY Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 870 659 467 403 187
Y / Y Equity Change 32.02 % 41.15 % 15.93 % 115.99 % 91.92 %
Net Income in Millions 159 145 129 181 35
Y / Y Net Income Change 9.07 % 12.91 % -28.99 % 424.52 % -
Return On Equity 18.24 % 22.07 % 27.59 % 45.05 % 18.55 %

Back to HRMY Management Effectiveness >> HRMY's 5 Years Annual ROE >> Compare HRMY ROE to its Competitors




Annual Roe Comment
In 2025 ROE fell to 18.24 %, despite net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HRMY's' Return on Equity at Yahoo Finance
HRMY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HRMY's Competitors
Subscribers only: Roe for Harmony Biosciences Holdings Inc 's Suppliers
Subscribers only: Return On Equity for HRMY's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %

Date modified: 2026-09-26T07:38:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.